An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer.
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Merck KGaA
- 09 Nov 2014 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 22 Feb 2013 Planned end date changed from 1 Jul 2014 to 1 Apr 2017 as reported by ClinicalTrials.gov.
- 25 Feb 2011 New source identified and integrated (Clinical Trials Registry - India, CTRI2010-091-000161).